| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Laparoscopy | 30 | 2014 | 492 | 3.440 |
Why?
|
| Prostatectomy | 14 | 2021 | 103 | 2.890 |
Why?
|
| Robotics | 15 | 2019 | 86 | 2.620 |
Why?
|
| Nephrectomy | 16 | 2020 | 93 | 2.560 |
Why?
|
| Urology | 8 | 2026 | 46 | 2.310 |
Why?
|
| Artificial Intelligence | 5 | 2026 | 209 | 2.260 |
Why?
|
| Prostatic Neoplasms | 12 | 2022 | 491 | 1.830 |
Why?
|
| Kidney Neoplasms | 13 | 2026 | 174 | 1.820 |
Why?
|
| Urologic Surgical Procedures | 7 | 2020 | 44 | 1.730 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2026 | 45 | 1.650 |
Why?
|
| Cystectomy | 6 | 2018 | 35 | 1.540 |
Why?
|
| Ureteroscopy | 6 | 2026 | 19 | 1.410 |
Why?
|
| Robotic Surgical Procedures | 5 | 2021 | 170 | 1.170 |
Why?
|
| Urinary Bladder Neoplasms | 7 | 2018 | 108 | 1.120 |
Why?
|
| Urinary Incontinence | 2 | 2019 | 44 | 0.980 |
Why?
|
| Urologic Neoplasms | 3 | 2024 | 19 | 0.910 |
Why?
|
| Documentation | 1 | 2026 | 132 | 0.890 |
Why?
|
| Men's Health | 1 | 2024 | 12 | 0.880 |
Why?
|
| Ureteral Neoplasms | 4 | 2026 | 10 | 0.860 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 105 | 0.840 |
Why?
|
| Urologists | 1 | 2023 | 3 | 0.790 |
Why?
|
| Kidney Transplantation | 4 | 2011 | 326 | 0.780 |
Why?
|
| Electronic Health Records | 1 | 2026 | 380 | 0.760 |
Why?
|
| Ureteral Obstruction | 4 | 2011 | 27 | 0.740 |
Why?
|
| Humans | 78 | 2026 | 64729 | 0.730 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2023 | 114 | 0.720 |
Why?
|
| Endoscopy | 5 | 2025 | 94 | 0.710 |
Why?
|
| Umbilicus | 6 | 2012 | 16 | 0.670 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 21 | 0.630 |
Why?
|
| Male | 48 | 2026 | 30790 | 0.620 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 60 | 0.610 |
Why?
|
| Ureteral Calculi | 1 | 2019 | 8 | 0.610 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 119 | 0.600 |
Why?
|
| Aneurysm, False | 1 | 2019 | 47 | 0.590 |
Why?
|
| Triage | 1 | 2020 | 126 | 0.570 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2008 | 8 | 0.570 |
Why?
|
| Postoperative Complications | 9 | 2026 | 1309 | 0.550 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.550 |
Why?
|
| Conservative Treatment | 1 | 2018 | 19 | 0.540 |
Why?
|
| Intraoperative Complications | 3 | 2015 | 89 | 0.520 |
Why?
|
| Living Donors | 4 | 2011 | 79 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 207 | 0.510 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.510 |
Why?
|
| Kidney Pelvis | 4 | 2010 | 13 | 0.510 |
Why?
|
| MicroRNAs | 5 | 2023 | 704 | 0.500 |
Why?
|
| Patient Positioning | 2 | 2015 | 50 | 0.490 |
Why?
|
| Prostate | 6 | 2022 | 122 | 0.490 |
Why?
|
| Postoperative Hemorrhage | 2 | 2015 | 39 | 0.480 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2014 | 126 | 0.460 |
Why?
|
| Intestinal Perforation | 1 | 2015 | 17 | 0.460 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 148 | 0.460 |
Why?
|
| Rectal Diseases | 1 | 2015 | 29 | 0.460 |
Why?
|
| Pandemics | 1 | 2020 | 669 | 0.450 |
Why?
|
| Lymph Node Excision | 2 | 2015 | 45 | 0.450 |
Why?
|
| Treatment Outcome | 17 | 2026 | 5758 | 0.420 |
Why?
|
| Drug Therapy | 1 | 2014 | 56 | 0.410 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 539 | 0.400 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 325 | 0.390 |
Why?
|
| Middle Aged | 30 | 2026 | 18106 | 0.380 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2013 | 39 | 0.370 |
Why?
|
| Kidney | 4 | 2020 | 451 | 0.370 |
Why?
|
| Laparoscopes | 3 | 2009 | 23 | 0.370 |
Why?
|
| Urinary Tract | 1 | 2012 | 10 | 0.370 |
Why?
|
| Aged | 25 | 2026 | 14834 | 0.350 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2026 | 369 | 0.340 |
Why?
|
| Surgical Mesh | 1 | 2011 | 60 | 0.330 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 640 | 0.330 |
Why?
|
| Hernia, Inguinal | 1 | 2011 | 41 | 0.330 |
Why?
|
| Ureter | 3 | 2016 | 37 | 0.320 |
Why?
|
| Pliability | 1 | 2009 | 6 | 0.300 |
Why?
|
| Female | 29 | 2026 | 33739 | 0.300 |
Why?
|
| Miniaturization | 1 | 2009 | 10 | 0.300 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2010 | 37 | 0.300 |
Why?
|
| Kidney Diseases | 2 | 2018 | 177 | 0.290 |
Why?
|
| Common Bile Duct Diseases | 1 | 2008 | 10 | 0.290 |
Why?
|
| Rectal Fistula | 1 | 2008 | 21 | 0.280 |
Why?
|
| Nephrolithiasis | 1 | 2008 | 8 | 0.280 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 52 | 0.270 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 167 | 0.270 |
Why?
|
| Retrospective Studies | 13 | 2026 | 6803 | 0.270 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 90 | 0.260 |
Why?
|
| Drainage | 1 | 2008 | 153 | 0.260 |
Why?
|
| Urinary Catheterization | 1 | 2006 | 20 | 0.250 |
Why?
|
| BCG Vaccine | 1 | 2026 | 56 | 0.240 |
Why?
|
| Glomerular Filtration Rate | 1 | 2026 | 120 | 0.230 |
Why?
|
| Butyrates | 1 | 2005 | 16 | 0.220 |
Why?
|
| Urinary Diversion | 1 | 2005 | 12 | 0.220 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 28 | 0.220 |
Why?
|
| Databases, Factual | 3 | 2020 | 879 | 0.220 |
Why?
|
| Adjuvants, Immunologic | 1 | 2026 | 235 | 0.220 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 5562 | 0.220 |
Why?
|
| Teaching Materials | 1 | 2024 | 12 | 0.220 |
Why?
|
| Cytoskeletal Proteins | 2 | 2005 | 204 | 0.220 |
Why?
|
| Natural Language Processing | 1 | 2024 | 52 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2026 | 148 | 0.210 |
Why?
|
| Efficiency, Organizational | 1 | 2024 | 92 | 0.210 |
Why?
|
| Adult | 18 | 2025 | 17230 | 0.210 |
Why?
|
| Prospective Studies | 6 | 2025 | 3299 | 0.200 |
Why?
|
| Health Literacy | 1 | 2024 | 87 | 0.200 |
Why?
|
| Prostate-Specific Antigen | 2 | 2021 | 84 | 0.200 |
Why?
|
| Comprehension | 1 | 2024 | 138 | 0.200 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 364 | 0.190 |
Why?
|
| Lasers, Solid-State | 1 | 2022 | 18 | 0.190 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2022 | 20 | 0.180 |
Why?
|
| Risk Assessment | 5 | 2020 | 2086 | 0.180 |
Why?
|
| Pelvic Bones | 1 | 2021 | 17 | 0.170 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 8 | 0.170 |
Why?
|
| Administration, Intravesical | 2 | 2026 | 14 | 0.170 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 6 | 0.170 |
Why?
|
| Nomograms | 2 | 2021 | 19 | 0.170 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 481 | 0.160 |
Why?
|
| Urethra | 3 | 2021 | 78 | 0.160 |
Why?
|
| Urogenital Neoplasms | 1 | 2020 | 5 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 2 | 2018 | 99 | 0.160 |
Why?
|
| Length of Stay | 3 | 2014 | 822 | 0.160 |
Why?
|
| Urethral Stricture | 1 | 2021 | 70 | 0.160 |
Why?
|
| Contraindications | 2 | 2011 | 52 | 0.150 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2019 | 15 | 0.150 |
Why?
|
| Kidney Function Tests | 2 | 2009 | 36 | 0.150 |
Why?
|
| Neoplasm Grading | 4 | 2021 | 94 | 0.140 |
Why?
|
| Nephroureterectomy | 1 | 2018 | 2 | 0.140 |
Why?
|
| Organ Sparing Treatments | 1 | 2018 | 17 | 0.140 |
Why?
|
| Crowdsourcing | 1 | 2018 | 15 | 0.140 |
Why?
|
| Preoperative Care | 3 | 2021 | 200 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2023 | 582 | 0.130 |
Why?
|
| Patient Care Management | 1 | 2018 | 30 | 0.130 |
Why?
|
| Ablation Techniques | 1 | 2018 | 26 | 0.130 |
Why?
|
| Kidney Calculi | 1 | 2018 | 34 | 0.130 |
Why?
|
| Quality of Life | 3 | 2011 | 1254 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 459 | 0.130 |
Why?
|
| Incidence | 2 | 2014 | 1409 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 792 | 0.130 |
Why?
|
| Enoxaparin | 1 | 2017 | 17 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2021 | 458 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 522 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 2753 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2018 | 575 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 260 | 0.120 |
Why?
|
| Heparin | 1 | 2017 | 118 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 524 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 727 | 0.120 |
Why?
|
| Incisional Hernia | 1 | 2015 | 15 | 0.120 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2015 | 14 | 0.120 |
Why?
|
| Lymphocele | 1 | 2015 | 5 | 0.120 |
Why?
|
| Social Media | 1 | 2018 | 126 | 0.110 |
Why?
|
| Equipment Failure | 1 | 2015 | 64 | 0.110 |
Why?
|
| Peritoneum | 1 | 2015 | 31 | 0.110 |
Why?
|
| Blood Vessels | 1 | 2015 | 63 | 0.110 |
Why?
|
| Survival Rate | 3 | 2018 | 847 | 0.110 |
Why?
|
| Inpatients | 1 | 2017 | 310 | 0.110 |
Why?
|
| Operative Time | 1 | 2014 | 91 | 0.100 |
Why?
|
| Surgical Flaps | 1 | 2015 | 116 | 0.100 |
Why?
|
| Learning | 1 | 2015 | 185 | 0.100 |
Why?
|
| Prognosis | 3 | 2021 | 1770 | 0.100 |
Why?
|
| Equipment Design | 3 | 2009 | 359 | 0.100 |
Why?
|
| Pelvis | 2 | 2015 | 61 | 0.100 |
Why?
|
| Time Factors | 3 | 2025 | 3745 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2026 | 91 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 797 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 2238 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 2483 | 0.090 |
Why?
|
| Biopsy | 3 | 2021 | 454 | 0.090 |
Why?
|
| Replantation | 1 | 2011 | 11 | 0.090 |
Why?
|
| Risk Factors | 2 | 2020 | 5393 | 0.090 |
Why?
|
| Sutures | 1 | 2012 | 39 | 0.090 |
Why?
|
| Anastomosis, Surgical | 2 | 2012 | 119 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 371 | 0.090 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2011 | 30 | 0.090 |
Why?
|
| Young Adult | 5 | 2017 | 4771 | 0.080 |
Why?
|
| Urologic Diseases | 1 | 2010 | 18 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2011 | 146 | 0.080 |
Why?
|
| Genes, Suppressor | 1 | 2010 | 6 | 0.080 |
Why?
|
| Feasibility Studies | 5 | 2011 | 579 | 0.080 |
Why?
|
| Warm Ischemia | 1 | 2009 | 3 | 0.080 |
Why?
|
| Matched-Pair Analysis | 1 | 2009 | 11 | 0.080 |
Why?
|
| Convalescence | 1 | 2009 | 18 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2009 | 64 | 0.070 |
Why?
|
| Ischemia | 1 | 2011 | 203 | 0.070 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 35 | 0.070 |
Why?
|
| Urachus | 1 | 2008 | 3 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 249 | 0.070 |
Why?
|
| Vascular Neoplasms | 1 | 2008 | 18 | 0.070 |
Why?
|
| Analgesics | 1 | 2009 | 102 | 0.070 |
Why?
|
| gamma Catenin | 2 | 2005 | 6 | 0.070 |
Why?
|
| Desmoplakins | 2 | 2005 | 10 | 0.070 |
Why?
|
| Dissection | 1 | 2008 | 46 | 0.070 |
Why?
|
| Graft Survival | 1 | 2009 | 297 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2008 | 48 | 0.070 |
Why?
|
| Adenoma | 1 | 2008 | 68 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2009 | 86 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2008 | 122 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2008 | 38 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2009 | 340 | 0.070 |
Why?
|
| Cadherins | 2 | 2005 | 90 | 0.070 |
Why?
|
| Hemostatics | 1 | 2008 | 27 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2023 | 1029 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 414 | 0.070 |
Why?
|
| Patient Simulation | 1 | 2008 | 67 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 285 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 194 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2009 | 400 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 2680 | 0.060 |
Why?
|
| Lidocaine | 1 | 2006 | 33 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 60 | 0.060 |
Why?
|
| Mitomycin | 1 | 2026 | 27 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2026 | 45 | 0.060 |
Why?
|
| Anesthetics, Local | 1 | 2006 | 71 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 433 | 0.060 |
Why?
|
| Animals | 5 | 2023 | 21292 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2026 | 242 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2025 | 2603 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 364 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 543 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2005 | 145 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 95 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2005 | 286 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 240 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 1210 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 493 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2005 | 373 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 344 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 870 | 0.050 |
Why?
|
| Algorithms | 1 | 2008 | 1033 | 0.050 |
Why?
|
| Watchful Waiting | 1 | 2022 | 32 | 0.050 |
Why?
|
| Hiccup | 1 | 2002 | 3 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 1556 | 0.050 |
Why?
|
| Language | 1 | 2023 | 153 | 0.050 |
Why?
|
| Laryngeal Masks | 1 | 2002 | 25 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2002 | 47 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1104 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2023 | 210 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2023 | 276 | 0.040 |
Why?
|
| Gastroesophageal Reflux | 1 | 2002 | 93 | 0.040 |
Why?
|
| Cell Movement | 1 | 2023 | 475 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 76 | 0.040 |
Why?
|
| United States | 1 | 2014 | 8041 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 11085 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 655 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1159 | 0.040 |
Why?
|
| Suture Techniques | 2 | 2012 | 94 | 0.040 |
Why?
|
| Terminology as Topic | 2 | 2010 | 144 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2020 | 298 | 0.040 |
Why?
|
| Transfection | 1 | 2021 | 700 | 0.040 |
Why?
|
| Cadaver | 2 | 2009 | 127 | 0.040 |
Why?
|
| Vagina | 2 | 2009 | 86 | 0.030 |
Why?
|
| Proteus mirabilis | 1 | 2018 | 2 | 0.030 |
Why?
|
| Proteus Infections | 1 | 2018 | 2 | 0.030 |
Why?
|
| Diverticulum | 1 | 2018 | 12 | 0.030 |
Why?
|
| Abdominal Abscess | 1 | 2018 | 13 | 0.030 |
Why?
|
| Confidentiality | 1 | 2018 | 58 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 483 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2021 | 518 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 64 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 969 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 260 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 1656 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 706 | 0.030 |
Why?
|
| Gallbladder | 1 | 2014 | 40 | 0.030 |
Why?
|
| Laparotomy | 1 | 2014 | 54 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 92 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 50 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 214 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 130 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 67 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 26 | 0.020 |
Why?
|
| Equipment and Supplies | 1 | 2009 | 19 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2009 | 59 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 426 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2009 | 78 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 867 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 241 | 0.020 |
Why?
|
| Vas Deferens | 1 | 2008 | 5 | 0.020 |
Why?
|
| Cystoscopy | 1 | 2008 | 17 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 289 | 0.020 |
Why?
|
| Seminal Vesicles | 1 | 2008 | 8 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 138 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2008 | 28 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2008 | 47 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2008 | 67 | 0.020 |
Why?
|
| Swine | 1 | 2008 | 394 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2009 | 270 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2008 | 154 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2005 | 16 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 898 | 0.010 |
Why?
|
| beta Catenin | 1 | 2005 | 99 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2009 | 723 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 214 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 610 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 321 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 1231 | 0.010 |
Why?
|
| Child | 1 | 2009 | 4599 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 6291 | 0.010 |
Why?
|